BioStock: Progress for Stayble Therapeutics in the second quarter
The second quarter was an intense period with several important achievements for the Gothenburg-based pharmaceutical company Stayble Therapeutics. After a successful capital raise, the company can run the two ongoing studies with STA363 at the desired pace. According to the plan, the phase IIb study in degenerative disc disease will be completed in the second half of 2023. The company also looks forward to treating the first patient in the phase Ib study in herniated discs.Read the full article at biostock.se: https://www.biostock.se/en/2023/08/progress-for-stayble-therapeutics-in-the-